2024/03/28 18:00:01 | |
---|---|
Price | |
101.761 CHF | |
Difference | -0.10% (-0.10) |
ISIN | US0028241000 |
Symbol | ABT |
Exchange | BX Swiss |
Currency | CHF |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 182,860 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 101.856 CHF (204) |
Ask (Ask size) | 102.124 CHF (204) |
Open | 101.761 CHF |
High | 101.761 CHF |
Low | 101.761 CHF |
Close (prev. day) | 101.863 CHF |
VWAP | 101.761 CHF |
Volume (pcs) | 1 |
Trading volume | 101.70 |
Number of trades | 1 |
Last size | 1 |
Related Futures | 15 |
Related Options | - |
Date | Headline | Download | |
2024/03/13 | Global Equity Ratings | ||
2024/02/22 | Global Equity Ratings | ||
2024/02/14 | Global Equity Ratings | ||
2024/01/23 | Global Equity Ratings | ||
2023/12/21 | Global Equity Ratings |
2024/03/28 18:00:01 | |
---|---|
Price | |
101.761 CHF | |
Difference | -0.10% (-0.10) |
ISIN | US0028241000 |
Symbol | ABT |
Exchange | BX Swiss |
Currency | CHF |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 182,860 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 101.856 CHF (204) |
Ask (Ask size) | 102.124 CHF (204) |
Open | 101.761 CHF |
High | 101.761 CHF |
Low | 101.761 CHF |
Close (prev. day) | 101.863 CHF |
VWAP | 101.761 CHF |
Volume (pcs) | 1 |
Trading volume | 101.70 |
Number of trades | 1 |
Last size | 1 |
6m | 1Y | 3Y | |
Perf (%) | +13.48% | +13.99% | - |
Perf (abs.) | +12.09 | +12.49 | - |
Beta | 0.31 | 0.43 | 0.73 |
Volatility | 28.72 | 29.81 | - |
Ø price 5 days | Ø volume 5 days (pcs.) | 100.908 CHF (3) |
Ø price 30 days | Ø volume 30 days (pcs.) | 103.330 CHF (23) |
Ø price 100 days | Ø volume 100 days (pcs.) | 97.835 CHF (16) |
Ø price 250 days | Ø volume 250 days (pcs.) | 95.671 CHF (9) |
YTD High | date | 106.295 CHF (2024/03/05) |
YTD Low | date | 93.629 CHF (2024/01/08) |
52 Weeks High | date | 106.295 CHF (2024/03/05) |
52 Weeks Low | date | 83.326 CHF (2023/10/17) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2024/03/28 | 17:35 | 104.82 EUR | 0.04 | 20 |
Vienna Stock Exchange | 2024/03/28 | 17:32 | 104.80 EUR | 0.00 | 1 |
Tradegate | 2024/03/28 | 22:26 | 105.36 EUR | 0.23 | 49 |
Stuttgart | 2024/03/28 | 09:08 | 105.02 EUR | 0.00 | 4 |
SIX Swiss Exchange | 2024/02/19 | 17:31 | 93.00 CHF | 0.00 | 1 |
NYSE | 2024/03/28 | 21:00 | 113.66 USD | 599.50 | 48,508 |
Munich | 2024/03/28 | 08:05 | 104.46 EUR | 0.00 | 2 |
London Stock Exchange | 2024/03/28 | 14:33 | 113.20 USD | 0.01 | 3 |
Hanover | 2024/03/28 | 08:10 | 104.48 EUR | 0.00 | 1 |
Hamburg | 2024/03/28 | 08:10 | 104.48 EUR | 0.00 | 1 |
Frankfurt | 2024/03/28 | 17:44 | 104.88 EUR | 0.03 | 3 |
Duesseldorf | 2024/03/28 | 19:31 | 105.30 EUR | 0.00 | 6 |
Berlin | 2024/03/28 | 20:30 | 105.66 EUR | 0.00 | 18 |
BX Swiss | 2024/03/28 | 18:00 | 101.761 CHF | 0.00 | 1 |
ABBOTT LABORATORIES |
- - |
100 Abbott Park Road - 60064-6400 Abbott Park |
Telefon: +1-224-667-6100 |
Fax: + |
E-mail: - |
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL. |
Robert Alpern | Member of Board of Directors |
Sally Blount | Member of Board of Directors |
Claire Babineaux-Fontenot | Member of Board of Directors |
Daniel Starks | Member of Board of Directors |
Darren McDew | Member of Board of Directors |
John Stratton | Member of Board of Directors |
Michael O'Grady | Member of Board of Directors |
Michael Roman | Member of Board of Directors |
Michelle Kumbier | Member of Board of Directors |
Nancy McKinstry | Member of Board of Directors |
Paola Gonzalez | Member of Board of Directors |
Robert B. Ford | Chairman of Managing Board |
John M. Capek | Member of Executive Committee |
Alejandro Wellisch | Member of Executive Committee |
Andrea F. Wainer | Member of Executive Committee |
Andrew H. Lane | Member of Executive Committee |
Christopher J. Calamari | Member of Executive Committee |
Daniel Salvadori | Member of Executive Committee |
Greg Ahlberg | Member of Executive Committee |
Hubert L. Allen | Member of Executive Committee |
J. Scott House | Member of Executive Committee |
Jared L. Watkin | Member of Executive Committee |
John F. Ginascol | Member of Executive Committee |
Joseph Manning | Member of Executive Committee |
Julie Tyler | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer